BioTuesdays

Tag - Kristen Kluska

Cantor starts Evelo Biosciences at OW; PT $28

Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...

Chemomab-Therapeutics

Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...

Lineage-Cell-Therapeutics-Logo

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

Heat Biologics

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

iBio Inc. Logo

Cantor Fitzgerald starts iBio at OW; PT $3

Cantor Fitzgerald launched coverage of iBio (NYSE American:IBIO) with an “overweight” rating and price target of $3. The stock closed at $1.46 on Jan. 21. iBio focuses on plant-made biologics manufacturing, which is...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.